Letters, Testimony & Comments

April 29, 2002
Ladies and gentlemen, good afternoon. I'm Carl Feldbaum, president of the Biotechnology Industry Organization, and I'm here today to report on the state of our industry, which is, from a big picture perspective, excellent. Biotechnology...
April 25, 2002
Robinsue Frohboese, Ph.D. Acting Director, Office for Civil Rights U.S. Department of Health and Human Services Attention: Privacy 2, Room 425A Hubert H. Humphrey Building 200 Independence Avenue, S.W. Washington, D.C. 20201   Re:...
April 23, 2002
Good morning, Mr. Chairman and Members of the Committee. My name is Dr. Charles Johnson. I am Associate Director of Specialty Biotherapeutics at Genentech, Inc., a leading biotechnology company headquartered in South San Francisco, California. I...
April 23, 2002
Good morning, Mr. Chairman and Members of the Committee. My name is Dr. Charles Johnson. I am Associate Director of Specialty Biotherapeutics at Genentech, Inc., a leading biotechnology company headquartered in South San Francisco, California. I...
April 11, 2002
Summary The biotechnology industry is the most research and development intensive and capital-focused industry in the world. The United States currently leads the world in the area of biotechnology because U.S. patent laws and legislation such as...
March 21, 2002
Ranking Member of the House Judiciary Committee
March 21, 2002
Chairman of the House Judiciary Subcommittee on Courts, The Internet, and Intellectual Property
March 21, 2002
Ranking Member of the House Judiciary Subcommittee on Courts, The Internet, and Intellectual Property
March 6, 2002
Mr. Chairman and Members of the Subcommittee, I am Mary K. Pendergast, Executive Vice President for Government Affairs at Elan Pharmaceuticals Management Corporation. I am pleased to be here today on behalf of the Biotechnology Industry...
March 3, 2002
BIO supports S. 1764, the Robert Stevens, Thomas Morris Jr., Joseph Curseen, Kathy Nguyen, Ottilie Lundgren, and Lisa Raines Biological and Chemical Weapons Research Act as introduced by Senator Joseph Lieberman. (Mar. 3, 2002).
February 26, 2002
The biotechnology industry is the most research and development intensive and capital-focused industry in the world. As such, it is very dependent on a robust intellectual property system as well as a strong set of competition laws. Recent...
February 5, 2002
Testimony of Dr. Una S. Ryan President and CEO, AVANT Immunotherapeutics, Inc. Before the Subcommittee on Science, Technology, and Space Senate Committee on Commerce, Science, and Transportation Tuesday, February 5, 2002   Mr....
January 8, 2002
FDA's Pediatric Rule Early Rule. In 1994 FDA issued a regulation requiring manufacturers of marketed drugs to survey existing data and to determine whether the data were sufficient to support additional pediatric use information in the...
December 13, 2001
For the second time this year, BIO along with PhRMA filed a petition for a write of certiorari before the Supreme Court. The petition filed on Thursday Eli Lilly and Company v. Barr Laboratories Inc., asks the Supreme Court to address and correct...
December 10, 2001
On December 10th, 2001, the Supreme Court held that Utility patents may be issued for plants under 35 U.S.C. 101 despite distinct protections available under the Plant Variety Protection Act and the Plant Patent Act. Affirming the Federal Circuit...